Kirby Doshier 00:00:00
Before we begin the formal briefing, I'd like to take a moment just to introduce the Parkinson's Foundation. As a nonprofit organization, we are dedicated to improving the lives of those living with Parkinson's by enhancing care and advancing research. Our efforts are deeply rooted in collaboration with the Parkinson's community, ensuring that everything we do aligns with your needs and your priorities. Today's program is just one example of how we are working with you to meet those goals. Real quick, I just wanted to share we have our annual Care Partner Summit coming up. I'd love to invite our care partners to join us Saturday, November 7th.
We understand that caring for someone with Parkinson's can be both rewarding and challenging, so we ask you to please join us for a supportive discussion on cognitive and mood changes, communication, caregiver well-being, and self-care. You can gain practical strategies, helpful resources, and encouragement to build resilience, find support, and navigate the caregiving journey with confidence. Whether you're new here or decades in, these conversations are designed to meet you where you are. You can learn more and register to attend at Parkinson.org/CareSummit, and that link is right at the bottom as well. Along with learning and connecting, some of you may be wondering how you can help drive change. Did you know that the Parkinson's Foundation now has an advocacy center?
This is an easy way to help make policy change on research, care, prevention, and other issues of importance to the Parkinson's community. Through our advocacy page on our website, you can send a pre-written message to your federal or state representatives to advocate for policy changes. Sign up for email updates on public policy and learn more about the Foundation's policy priorities and other ways to take action. Just a friendly reminder that we're recording today's expert briefing. The recording will be available online in the coming days. We'll also be emailing you a link along with other resources related to today's topic. Perfect. Now, as we begin, I'm pleased to introduce our speaker today. We're delighted to welcome Dr. Bianca Palushaj.
She is a clinical assistant professor in the Department of Neurology and Neurological Sciences at Stanford University School of Medicine, where she completed her neurology residency and a fellowship in movement disorders. Her clinical and research interests center on the microbiome-immune-brain interaction in Parkinson's disease. She focuses on treating the gastrointestinal symptoms of Parkinson's to improve quality of life, and on the potential for gut-targeted therapies to modify disease progression. Her long-term goal is to bring these therapies to clinic for people at risk of neurodegenerative disease at a stage where neurodegeneration can still be prevented.
Kirby Doshier 00:02:37
Dr. Palushaj is an investigator on several studies of gut-brain communication in Parkinson's disease, and serves as the core clinical lead at Stanford for the NIH-funded Gut-Brain Parkinson's Disease Consortium. Thank you for sharing your time and expertise with us, Dr. Palushaj. We're excited to learn about the gut-brain connection in Parkinson's disease from you today.
Dr. Bianca Palushaj 00:02:57
Wonderful. Thank you so much, Kirby. And let me just pull up my slides here. Okay. Thank you, Kirby, and to the entire Parkinson's Foundation for inviting me to be here. I'm really honored and very excited to talk today about how the gut-brain connection in Parkinson's disease and how digestive health affects Parkinson's. These are my disclosures and our learning objectives for today. So, to understand how the gut and the brain influence each other and why it matters for people with Parkinson's, we're going to learn about new research and explore the gut's possible role in Parkinson's symptoms as well as progression.
So this includes the role of inflammation, the spread of alpha-synuclein, as well as things called short-chain fatty acids. And then we'll explore how future treatments might include gut-targeted therapies as part of Parkinson's care. So, as you may know, one of the earliest descriptions of Parkinson's was in 1817 by Dr. James Parkinson, and he described six cases of people with this condition in his essay called "The Shaking Palsy," and even in this early description, he noted that people with this condition had difficulty moving their bowels. And today, we think that anywhere from 60 to 90 percent of people with Parkinson's experience constipation.
And for decades, the conversation about GI dysfunction and Parkinson's has centered on constipation, but in reality, the picture is much broader than what we once appreciated. And so, dysfunction can occur, and often does occur, at every level along the GI tract, anywhere from the mouth to the rectum. And so, I won't read through this full list, but just to give a few examples of different types of GI dysfunction that can occur. People with Parkinson's have higher rates of dental caries and periodontal disease. They're more likely to have H. pylori infection in the stomach, which can impact how well the body absorbs levodopa, and also more likely to have reduced stomach acid.
And then Parkinson's can cause slowness throughout the entire GI tract, so slowness of the stomach emptying into the small intestine, as well as slow motility in both the small and the large intestines. And not only is GI dysfunction common throughout one's disease course, but it often starts years or even decades before motor symptoms start. And so, constipation is recognized by the Movement Disorders Society as a prodromal marker of Parkinson's disease. And on the right, you see that constipation isn't the only GI symptom that can precede the diagnosis. So heartburn or dysphagia, trouble swallowing, and dry mouth can all appear in the years before someone is diagnosed.
And so, this pre-motor GI dysfunction has intrigued scientists for decades, and it's pushed researchers to look more closely at the gut itself. And in particular, we focused on the enteric nervous system, which is a network of nerve cells that are built into the walls of the GI tract. It contains about 500 million neurons, which is more than the amount of neurons in the spinal cord. And it allows the gut to run largely on its own, independent of any control or signals from the brain. And so this is why it's often called the second brain or the little brain. And it's inside these gut neurons that we look for the hallmark of Parkinson's, which are those clumps of the protein alpha-synuclein.
Dr. Bianca Palushaj 00:06:26
And in autopsy studies of people with an established diagnosis of Parkinson's, nearly everyone has alpha-synuclein distributed throughout the GI tract. And the number of sites that are positive for alpha-synuclein correlates with worse motor symptoms and worse GI symptoms. In addition, alpha-synuclein can also be found in the GI tract of people in the prodromal phase, so years before they develop motor symptoms. So, to summarize this, we started with the recognition that GI dysfunction, and in particular constipation, is a common symptom of Parkinson's. And then we learned that it often appears years or even decades before the motor symptoms, which made constipation a recognized prodromal marker of the disease.
And this raised this question: Does Parkinson's actually start in the gut?
And indeed, autopsy studies have shown alpha-synuclein in the GI tract of people with prodromal Parkinson's years before motor symptoms start. And this brings us to the next question: If alpha-synuclein is clumping in the gut this early, what's triggering alpha-synuclein to misfold in the gut in the first place? And so, one leading hypothesis goes like this: It starts with an inflammatory trigger in the gut, and that could be certain types of gut bacteria, or it could be an environmental toxin like a pesticide. But either way, this switches on the immune system in the gut, and the result is gut inflammation. From there, gut inflammation can push Parkinson's forward along two main routes: the protein route and the inflammation route.
And so, on the left is the protein route. And so, inflammation causes the gut's nerve cells to make more alpha-synuclein. It increases the expression of alpha-synuclein, and the inflammation also encourages that protein to misfold and to clump. And then those clumps can travel up the vagus nerve, the gut-brain highway, where they can enter the brain. On the right is the inflammation route. So again, gut inflammation can make the gut lining leaky or cause intestinal permeability, and this can do two things. It can let oxygen into the gut, which is supposed to be an oxygen-free environment, and this can favor harmful bacteria. And then it also lets things out of the gut.
So bacterial byproducts and other inflammatory molecules can leave the gut and go into the bloodstream, which results in systemic inflammation. That inflammation can then reach the blood-brain barrier, which can cause leakiness of the blood-brain barrier. And once the brain's protective barrier is breached, you get inflammation inside the brain and ultimately the loss of nerve cells. And then you'll also notice this loop on the top right, where inflammation also damages or is detrimental to the healthy or the commensal gut microbes, which can make the gut more vulnerable to the next trigger and creates this vicious cycle. So within this model that I just showed, one potential cause of inflammation in the gut is the gut bacteria or the gut microbiota.
Dr. Bianca Palushaj 00:09:27
So the gut microbiome refers to this collective community of trillions of microorganisms. It includes bacteria, but we often forget about archaea and viruses, fungi, protozoa, and they all reside within the GI tract. And the highest concentration is in the large intestine or the colon. And this community of organisms performs numerous functions that are critical to our health. For example, they break down and they harvest energy from the food that we eat. They produce certain vitamins that we can't make on our own, like B vitamins and vitamin K. The gut bacteria can also produce neurotransmitters, so some gut bacteria can synthesize dopamine or the precursor to dopamine.
And likewise, certain bacteria can metabolize levodopa, which can impact the absorption and the response of levodopa.
The gut microbiome also heavily impacts our immune system, and 70% of our immune system resides in the gut. And then these bugs engage in bug-on-bug warfare, where the so-called good bugs or the commensal bugs can fight off bad or pathogenic bacteria. And we think that the gut microbiome weighs about as much as the brain and has the metabolic capacity of the liver, and so it's often referred to as this invisible organ that controls our immune system and our metabolic system, our nervous system, and is really shaping our behavior as well as our health. This is one of my favorite images relating to the gut microbiome, and it's produced by a group here at Stanford.
And I like it because it really beautifully shows this spatial relationship of different elements of the gut. So the pink, yellow, and orange that you see in the top left are the microbes. The blue area and the lower corner are the cells that make up the wall of the colon, and then separating those two is this thick green layer, which is mucus that's secreted by those colonocytes or the colon cells, and forms this mucus barrier. And what you can't appreciate is that inside that blue gut wall, there's immune cells and nerve cells that are constantly sensing what's happening inside the gut. And these cells are exposed to the bacteria, the bacterial byproducts, various things that we ingest, as well as any inflammatory signals.
And I think this picture makes it really easy to see why that thick green mucus layer is so critical, because it separates the outside world, which is inside the gut lumen, from our own nervous and immune systems. And so this protective mucus barrier can be degraded through a variety of mechanisms. But one way that this happens is through a diet that's deficient in fiber. So when fiber is lacking in our diet, the microbes shift from consuming our dietary fiber to actually consuming this mucus layer.
And as they eat away at this layer, it thins this protective barrier, which allows bacteria and associated products to then come closer to that blue gut wall that's lined with nerve cells and immune cells, and that can trigger inflammation. So I've introduced you to the microbiome, and I'm going to take us back to that question: if alpha-synuclein is clumping in the gut early, why? What's triggering it there? So there's been some really interesting studies in animal models suggesting that something about the gut microbiome may cause alpha-synuclein to aggregate. So this is a study from the lab of Sarkis Mazmanian using ASO mice.
Dr. Bianca Palushaj 00:12:45
So this is a common animal model of Parkinson's, and so these mice are genetically engineered to overexpress alpha-synuclein. And what they found is that the mice that do not have a microbiome, they're germ-free mice, have less alpha-synuclein aggregates in the brain and decreased brain pathology compared to the same type of mouse that has a gut microbiome. So I draw your attention to this immunofluorescence photo in the center, and you see that on the right. Which is the germ-free mice without a microbiome. There's less alpha-synuclein pathology, which is depicted in the red and the green, in those germ-free mice that lack the gut microbiome.
And what the other figures are showing us is just that that germ-free mouse is still expressing alpha-synuclein. The alpha-synuclein just isn't aggregating. So again, something about the microbiome seems to be inducing alpha-synuclein aggregation. So, how might gut bacteria cause alpha-synuclein in the gut to aggregate? So, I'm going to take a step back. As a reminder, alpha-synuclein is what we call an amyloid protein, and this just means that it can misfold from its normal soluble shape into an insoluble aggregated one that has a very particular structure. And it turns out that alpha-synuclein isn't the only amyloid in the gut, but some bacteria can make their own amyloid proteins.
And the best studied example of this is a protein that's called curli, which is produced by E. coli. And at the molecular level, this bacterial protein curli looks strikingly similar to the abnormal human amyloid proteins, like amyloid beta in Alzheimer's disease and alpha-synuclein in Parkinson's disease. And this structural similarity matters for two reasons. First, the immune system can't tell a difference, so it recognizes curli using the same receptors that it uses for human amyloid, and the result is inflammation. And second, there's preclinical evidence, meaning that this is not in humans, that curli can act as a seed. So when it comes into contact with normal human alpha-synuclein, it can template that protein into a misfolded shape and set off aggregation.
And this is what we call cross-seeding. And so in mouse models, if you feed animals curli-producing E. coli, it actually worsens alpha-synuclein pathology and motor deficits, while feeding them E. coli that can't make curli does not do this, and curli is just one example. But we're finding that there are thousands of gut bacteria that produce amyloid proteins of their own, and so this is one plausible explanation for what I just showed you, which is that mice raised without any gut microbiome develop less alpha-synuclein pathology in the brain. So, what do we know about the gut microbiome in Parkinson's disease? And before I answer that, let me just set the stage with two important points.
Dr. Bianca Palushaj 00:15:36
So, the first is that because different bacterial species can carry out the same function, or in other words, a single function can be performed by many different species, the field has really shifted its focus away from which specific bugs are present, and toward trying to understand what's the functional capacity of these bugs and what metabolites do they produce. The second point is that we still don't really have a well-defined picture of what a normal gut microbiome function really is. So, still trying to understand what the microbiome's core functions are and what the normal reference ranges are for those functions.
So, with these points in mind, what's well established is that the composition, meaning what bugs are there, as well as the function of these bugs, is clearly altered in people with Parkinson's compared to controls. And this holds up not just if you compare people with Parkinson's against population controls, but also if you compare them against matched household controls. So those are people who are sharing the same pets and water source, diet, and general lifestyle. So this strengthens the case that this isn't just confounding by other exposures that can impact the microbiome.
Another reproducible finding is that there is a decrease in anti-inflammatory bacteria as well as the anti-inflammatory molecules that they create, and there is an increase in markers of gut inflammation.
And even though this isn't specific to Parkinson's, there is a depletion of beneficial microbes that are capable of fermenting fiber into an anti-inflammatory molecule that's called a short-chain fatty acid. So let's take a minute on short-chain fatty acids because these molecules are critical modulators of human health, and they're reduced in people with Parkinson's. So gut bacteria break down what we eat, and they transform it into these chemical compounds that go into circulation. And these compounds act as messengers to distant sites of the body. And this is one of the main ways that the microbiome influences the brain and other organs. And one type of these bacterial byproducts are short-chain fatty acids. The most common are butyrate and propionate.
And these molecules have a really long list of beneficial effects. I'll tell you just a couple. So they serve as energy sources for our colonic cells, the colonocytes, and in particular, when there's a reduction of short-chain fatty acids, this can drive a metabolic shift in the colon cells to something called anaerobic glycolysis, which is pro-inflammatory, and it increases oxygen content inside the gut, which further supports the growth of pathogenic aerobic bacteria. So it supports the growth of bacteria that we don't want in the gut. Short-chain fatty acids also strengthen the physical barrier of the gut in many ways, and a stronger gut barrier often means reduced immune activation.
Dr. Bianca Palushaj 00:18:34
And then they're also key regulators of immune response, both within the gut as well as systemically. So let's look at an example of how fiber, which is a substrate for short-chain fatty acid production, decreases inflammation in the brain. So here I'm showing you experimental evidence from animal models, and again these are ASO mice; they're alpha-synuclein overexpressing mice. And what we're looking at is the microglial cell, which is the resident immune cell in the brain. And so, when microglial cells are resting, they have these fine, long branches that have a high number of segments and a high number of branch points. And then, when these cells get activated into a pro-inflammatory state, they take on thicker, short branches with fewer segments.
And so we see an example of this in the bottom left, which is an activated pro-inflammatory microglial cell in that Parkinson's animal model that's on a controlled diet. And the main finding here is that when this microglial cell in the bottom left from the Parkinson's model is fed a prebiotic fiber, that morphology changes into the resting state. So the microglial cell has thinner, longer branches with more segments, and it looks very similar to that control microglial cell. So, experimental evidence that fiber, which is a prebiotic, meaning that it's food for the bacteria, dampens inflammation in the brain, and this is most likely through the production of short-chain fatty acids and other anti-inflammatory bacterial byproducts.
So when we think about disease risk, we usually think about exposure. So what happens to someone that puts them at risk? And we think much less about vulnerability. What might someone be lacking that would otherwise protect them?And so, short-chain fatty acids might be this kind of missing protection. So, over a lifetime, inevitably, we all accumulate environmental and lifestyle exposures like diet, pollutants, infections, stress. Collectively, these exposures are now being referred to as the exposome, and much of its harm runs through generating inflammation. And short-chain fatty acids are one of the body's key defenses against that inflammatory load.
So, as short-chain fatty acids decline, that balance tips, and the exposome-driven inflammation starts to outweigh the body's defenses, and the result can be chronic inflammation and, over time, chronic disease. So the last data that I'll show you on the microbiome in Parkinson's is some from our own research at Stanford, and this is from a cohort of people with Parkinson's and their matched household controls. So in most cases, this was a spouse, and again, this pairing with a household participant is really important for microbiome research because it allows us to isolate disease-specific changes of the microbiome.
And so, in this analysis, we applied a new method to directly count the total number of bacteria that are in the gut, and we found that people with Parkinson's had significantly fewer gut bacteria than their household control. And so, when we combine this finding of a depletion of the total amount of bacteria in the gut with other findings that predominantly show a loss of those beneficial microbes and their byproducts, we think that the gut environment in Parkinson's might become less supportive or less hospitable to bacterial growth overall. And there's many reasons why this shift could happen.
Dr. Bianca Palushaj 00:21:25
Some examples could be increased inflammation, increased oxygen levels that result from the degradation of the gut barrier and intestinal permeability, and potentially altered diet.
Okay, so now we're going to get practical, and hopefully this will cover most of the questions that were sent in ahead of time. But my goal here is for you to walk away with some concrete, evidence-based practices that you can implement starting today to support this community of bacteria that's living inside of you. So again, dietary fiber is really the fuel for the gut microbiome. So our own digestive enzymes are able to digest sugars and fats and proteins, and so these get absorbed in the small intestine, where they're taken up into circulation.
However, fiber passes through the small intestine undigested, and it reaches the colon and becomes the food for the gut bacteria, which again ferment it into those short-chain fatty acids like butyrate and propionate, and then that enters systemic circulation and has anti-inflammatory effects throughout the body, and also stimulates endogenous release of GLP-1s. So we're aiming for 30 to 40 grams of fiber per day in order to support the gut microbiome and also to help manage constipation. And so one rule of thumb that I like to think about is aiming for 10 to 15 grams of fiber per meal. And depending on how much you're eating today and what your baseline is when you're increasing fiber.
You want to start low and go slow in order to minimize GI distress, like bloating and gas, that can happen with increasing fiber. And this is probably even more important for people with Parkinson's disease, who often have gastroparesis or delayed gastric emptying, or small intestinal bacterial overgrowth or SIBO, which can aggravate symptoms related to fiber. You also want a diversity of fiber sources because different fibers feed different bacterial communities, and they help sustain diversity of the microbiome. So, 30 to 40 grams of fiber, diverse source of fiber-rich foods. In addition to fiber, you really want to add fermented foods. So these are foods and drinks that are transformed by beneficial microbes.
Dr. Bianca Palushaj 00:24:14
So this could be bacteria or yeast or both, into into these bioactive compounds that are responsible for the beneficial health effects of these foods. And so what we know is that if a gut microbiome is depleted, and it lacks the bacteria that can convert fiber into short-chain fatty acids, then just adding more fiber into the diet is unlikely to increase short-chain fatty acid production or to reduce inflammation. But fermented foods work differently. So by supplying the bacteria themselves, they increase the diversity of the gut. And by supplying the bioactive compounds that result from that fermentation process, they also decrease inflammation.
And so there was a landmark study on this topic that was published in 2021 out of the Sonnenburg Lab at Stanford, and they compared a diet high in fermented foods against a high-fiber diet, and they looked at the effects on the microbiome as well as the immune system. And what they found is that someone's response to the fiber diet depended on what their baseline microbiome looked like. However, the response to the fermented food diet was that everyone showed an increased bacterial diversity and decreased systemic inflammation, regardless of what their baseline microbiome looked like. And so, on the right, there's just some examples of fermented foods that you might want to try.
So when thinking about how to support the microbiome, I really think about these two levers. There's what we want to add and what we want to try to minimize or remove. And we talked about what we want to add, but in terms of what we want to take away, we want to try to minimize or reduce the following. So of course, ultra processed foods. These are associated with reducing bacterial diversity and also associated with a pro-inflammatory microbiome profile. The additives that are found in many ultra-processed foods, like emulsifiers and artificial sweeteners, can decrease those beneficial short-chain fatty acid-producing bacteria. And then pesticide residue can actually have a direct negative effect on the microbiome.
And there's some great apps out there to help you be an informed consumer when it comes to food, but also to body products and household products. So Yuka is an app that can be used to scan food barcodes, and then the Environmental Working Group, or the EWG, has an app that can be used for body and household products to help us decipher the millions of ingredients that are out there. We know that exposure to pesticides is a risk factor for developing Parkinson's, but as I mentioned, they also have a negative impact on the microbiome.
And so, harking back to that gut inflammation model that I shared, minimizing ongoing exposure to pesticides and other toxicants can help reduce gut inflammation, and in turn could possibly slow disease progression. So, when possible, I recommend trying to eat organic, but this isn't always feasible, and so this is why I recommend paying attention to the Environmental Working Group's Dirty Dozen and Clean Fifteen list that you can find on the website. So the Clean Fifteen are produce items where the pesticide residue doesn't differ significantly between the organic and the conventional versions.
Dr. Bianca Palushaj 00:27:32
And the other point is just to keep in mind that even organic produce carries some pesticide residue, and then food picks up other chemicals as it moves through transport and the food system. So you want to wash or soak your produce, regardless of whether it's organically or conventionally grown. So there were a lot of questions submitted about probiotics, and the short answer here is that there's no substantial evidence that probiotic supplements promote microbiome health. And there's a handful of reasons why this is probably the case at this time. First is just that delivery is really hard.
So getting live microbes through the stomach and the small intestine to the colon where they need to act is not a trivial task. The second point is that every microbiome is very unique, and supplements are built on this assumption that the same strain is going to help everyone. But in reality, what benefits one person might not help someone else. So the handful of strains that are available on the market might simply not be what your gut needs. And then another consideration is the dose of supplements is often not physiologic. So a capsule delivers typically billions to trillions of microbes, whereas fermented foods deliver hundreds of thousands to millions. And more is not necessarily better here.
So these mega doses of a few strains can actually crowd out the favorable microbes that you already have. And I'd say the clearest demonstration of this concept was a study of people that were recovering from antibiotics, and those people who took a probiotic supplement took more than five months for their microbiome to recover, whereas those who took a placebo took about three weeks for their microbiome to recover. And then the last point I'll make is just that food brings more than just the microbes. So again, fermented foods carry the metabolites and signaling molecules that supplements don't have, and we think that these metabolites and signaling molecules might also be helpful for colonizing beneficial bacteria in the gut.
So diet is really complicated, and of course, food carries cultural meaning, and it's social, and it's emotional, and it's never just about nutrients on a plate. And also, studying diet is really genuinely hard because people don't eat single ingredients. We eat meals, and we don't always remember or report what we ate. And so the evidence in studying diet is messier than I think any of us would like. And so, rather than chasing the perfect diet or a specific diet, I advocate for a simpler reframe, and this is a microbiome-targeted diet. And so, the question really becomes, what am I feeding my microbiota today? Have I eaten a diversity of plant foods that provide fermentable fiber? Have I eaten fermented foods?
Dr. Bianca Palushaj 00:30:18
Because, as I hope I've demonstrated, when you feed your microbes the right raw material, they feed you back with compounds that support your gut and your brain and your whole body. Okay, so we'll change gears and we'll talk about the management of constipation and Parkinson's. And the first thing that I want you to know is that not all constipation in Parkinson's is the same. So there's two causes of constipation. We have slow-transit constipation and dyssynergic defecation, and this matters because the treatments for these two types of constipation are not the same. So, slow transit constipation can cause infrequent bowel movements and symptoms like bloating and abdominal distension that builds between bowel movements.
It's diagnosed by a colonic transit study, and we treat it with laxatives, which we're going to talk about. Dyssynergic defecation results from the loss of coordinated anorectal neuromuscular control. So it's the incoordination of pelvic floor muscles and sphincters that can cause outlet obstruction. And we think that this occurs in about 60% of people with Parkinson's, and it doesn't respond to laxatives. What we do think is that dopaminergic treatment can improve dyssynergic defecation, or in other words, this dyssynergic defecation-related outlet obstruction can be worse in off states. So symptoms of dyssynergic defecation include prolonged time on the toilet, a sense of incomplete evacuation, or needing multiple attempts throughout the day, and it can also be painful.
It's diagnosed by a procedure that's called anorectal manometry, which is performed by our colleagues in gastroenterology, and it's treated with pelvic floor physical therapy and biofeedback. Importantly, the presence of dyssynergic defecation can also worsen slow transit constipation through this feedback loop. So when there's distension of the rectum due to stool, this can further slow gastric emptying and colonic transit. So how do we manage slow transit constipation? There's several tiers or angles that we can approach this with, and I'd say most often we'll need multiple of these. In terms of diet, fiber and hydration are still your first line. So again, for fiber, start low, increase slowly, and aim for 30 to 40 grams of diverse fiber sources per day.
In a second, I'll show you some fruits that have some natural laxative properties that you can also kind of work into your diet. The next tier is over-the-counter supplements and laxatives, and then there's several prescription medications that can be prescribed either by your neurologist or your gastroenterologist if you have one. And then there's some helpful lifestyle tricks that I'll discuss as well. So here's some fruits that can have natural stimulant properties. Kiwi has actually been studied in randomized controlled clinical trials compared to psyllium, and has been shown to increase stool frequency at a dose of two kiwis per day. So this is the fruit, not the supplement, and it's without the skin.
Dr. Bianca Palushaj 00:33:15
And then in terms of over-the-counter supplements, osmotic laxatives are generally the first line. So these are things like MiraLAX and magnesium oxide. And these should be taken every day for someone that has slow transit constipation. Next are stimulant laxatives like senna or bisacodyl, and these can be added as needed when the osmotic laxatives are not enough. And then I often get asked about, certain situations are kind of rescue medications, and specifically with travel, and aloe vera capsules can be used as rescue. And so the important thing to know here is that there's limited data on long-term use, so it's really just short-term, as-needed use of aloe vera capsules.
Beyond medications, there's a couple of other practical tips to try for constipation. So the first thing is toilet posture. So using a footstool to elevate the knees above the hips, and then adopting this forward-leaning trunk posture can improve defecation. And pictured on the right is how squatting, like this, relaxes this muscle around the rectum. That's called the puborectalis. And in doing this, it straightens the angle of the rectum, which allows for easier evacuation. And studies do show that squatting both reduces the time needed to defecate, and it also leads to a greater sense of complete evacuation. The second point is to schedule toileting during a reliable on period.
So remember, I told you that dyssynergic defecation, or that incoordination of the pelvic floor muscles that leads to outlet obstruction, can get better with levodopa and worse in the off state. So attempting to use the bathroom when medications are working improves the mechanics of straining and the pelvic floor coordination. Third point is to build a routine. So in Parkinson's, rectal afferent sensation can be blunted. So the urge to defecate can become an unreliable signal for going to the bathroom. So that's why it's recommended to try to build in a regular toileting routine rather than waiting for an urge. And then the last point is just to always think about medication.
So review your medications with your physician, and remember that commonly prescribed things like calcium channel blockers and iron supplements can contribute to constipation. Okay, in the last portion of the talk, I'm going to introduce some emerging gut-targeted therapies for Parkinson's disease. The first is fecal microbiota transplants, or I'll just refer to it as FMT. And you might have heard of this already because it's an FDA-approved treatment for C. diff infection and has really remarkable cure rates of about 90%. But more recently, it's become an area of interest in Parkinson's as well. Preclinical studies have been really promising, so they consistently show that if you transplant stool from healthy animal models into Parkinson's animals, it improves motor symptoms, it reduces alpha-synuclein aggregation, and it decreases neuroinflammation in those Parkinson's animals.
Dr. Bianca Palushaj 00:36:03
But so far, the translation into humans has been mixed. The first randomized controlled trial of FMT in Parkinson's was in 2023, and since then there's been about seven trials that have been published. Most of these are out of China. And the results are most commonly assessing changes in motor function. Sometimes the secondary endpoint is changes in constipation or changes in GI symptoms. But these results have been really mixed, and I'd say that the glaring issue here is that this process has not been standardized at all, so there's a lot of questions that need to be worked out. Like, what's the route of administration?
Do we administer through upper GI or through lower GI, like endoscopy or colonoscopy? How effective are oral capsules? Do we need to pre-treat with antibiotics? What's the number of doses that are needed? And how do we support engraftment? Meaning, how do we make the changes last once the treatment is withdrawn? I'll just add that no studies to date have included dietary guidance in order to support the engraftment of the transplant, despite the fact that we know that diet plays a major role in shaping the microbiome. Thus far, studies of the gut microbiome and its metabolites have relied entirely on stool. But we know that bacteria vary along the GI tract based on the microenvironment.
So, for example, changes in pH and nutrient availability, and by the time the contents reach stool, that regional signal has been homogenized away. So we haven't really been able to study any of these regional differences. The other point is that the small intestine is mostly unexplored because, in order to sample the luminal content, it requires an invasive procedure. But recently, there's been development of ingestible capsules that can sample luminal contents along the GI tract, including the small intestine and the proximal colon. And so the figure on the right is just showing this divergence, where we capture different species in the stool that's pictured in brown compared to the capsule device, it's pictured in blue.
And so, looking ahead, I think we'll move toward a more accurate, spatially resolved picture of the gut microbiome and its metabolites, including the ability to better understand the small intestine and its own distinct ecosystem, and this could translate into the ability to perform more comprehensive fecal microbiota transplants, where we can transplant the entire GI microbiome rather than just that distal colonic portion that we get from stool. Another potential gut-targeted therapy for Parkinson's is anti-amyloid therapy. So we talked about how bacteria produce amyloid proteins, like that curli protein from E. coli, and this causes gut inflammation, and it may seed the aggregation of human amyloids like alpha-synuclein.
Dr. Bianca Palushaj 00:39:01
And so the idea here is to use small molecules that bind to bacterial amyloid proteins, like curli. And that could prevent those proteins from inciting gut inflammation, and also remove one potential trigger of alpha-synuclein aggregation in the gut. A similar but different approach would target the host side of the equation. So the gut bacteria produce, of course, beneficial metabolites like those short-chain fatty acids, as well as harmful metabolites. And the obvious response would be to go after the bacteria themselves, try to wipe out the bad actors, or rebuild the whole community through something like fecal microbiota transplant. But as I mentioned, changing the gut ecosystem is hard to do, and it's even harder to make it last.
And so, a different approach, one that kind of sidesteps that problem entirely, is targeting the host instead of the bacteria. So, these harmful metabolites work by binding to specific receptors on our host cells. So, if you block that receptor, you could block the downstream deleterious effects without needing to change the microbiome. And then a final example is not direct manipulation of the gut or the microbiome, but instead indirect modulation of the gut via the vagus nerve. So the vagus nerve is the main nerve of the parasympathetic nervous system. This is the rest and digest counterbalance to the fight or flight. And so when the vagus nerve and the parasympathetic nervous system are active, it slows the heart rate.
It promotes digestion and it helps the body settle after stress. It also has a pro-inflammatory role. So vagal activation triggers a signaling cascade that dampens the release of inflammatory cytokines, and we can activate the vagus nerve non-invasively through something called vagal nerve stimulation. And there's two approaches to this, with a device on the neck that's pictured here, or with a small device in the ear, where there's dense innervation of a branch of the vagus nerve, and this treatment, non-invasive vagal nerve stimulation, is already FDA approved for the treatment of chronic migraines, but it hasn't been extensively studied in Parkinson's yet. Existing literature does show that it can improve constipation as well as insomnia.
And it also can dampen gut inflammation by reducing pro-inflammatory T cells in the gut tissue. So I'm hopeful that this could be a pretty simple, non-invasive way to modulate gut function, as well as other common symptoms of autonomic dysfunction in people with Parkinson's. And I want to close by just sharing a new national collaboration on gut-brain communication in Parkinson's that's funded by the National Institutes of Health and reflects how much interest and recognition this topic has gained. So again, constipation has been the face of GI dysfunction in Parkinson's for centuries now, but we recognize two things: that GI dysfunction is far more widespread than constipation.
Dr. Bianca Palushaj 00:41:54
And that disruption of GI homeostasis might actually play a role in how the disease develops in the first place. But what we don't have yet is a systematic look at this in large cohorts of people with Parkinson's over time, and so that's the gap that this study is designed to fill. So the National Institute of Diabetes and Digestive and Kidney Diseases, or the NIDDK, has funded a study of gut-brain communication in Parkinson's, and it spans the seven sites that are shown here. And each site pairs neurologists with gastroenterologists and a wider team with this goal of deeply characterizing GI dysfunction in people with Parkinson's across disease stages and over time.
And ultimately, the hope is that this knowledge leads to better treatments, therapies that relieve symptoms, and maybe even ones that change the course of the disease. And I think more broadly, it raises the possibility that the future of treating or even preventing neurological disease might lie outside of the brain. So here's what I want you to take away from today. GI dysfunction in Parkinson's is common. It often occurs before motor symptoms, and it can span the entire GI tract. And we're starting to study this systematically in large cohorts. The gut helps to regulate brain homeostasis, and gut inflammation can perpetuate neuroinflammation.
The gut microbiome in people with Parkinson's is depleted, both in anti-inflammatory short-chain fatty acid-producing bacteria and in the total amount of bacteria, suggesting that the gut ecosystem might not support healthy bacterial growth. And food is always better than supplements. So eat fiber and eat fermented foods in order to fuel the good bacteria and to supply the bacteria that are necessary to derive the benefits of a fiber-rich diet. And emerging Parkinson's treatments that target the gut-brain axis include vagal nerve stimulation, fecal microbiota transplant, and microbiota-targeted therapies. Thank you for your attention.
Kirby Doshier 00:44:04
Amazing. Thank you, Dr. Palushaj, for this discussion. Let me turn my video back on here. Awesome. All right. Now, before we jump into the questions, for those in the audience, we just want you to know that our team is organizing questions as they come in. So, please understand that the topic specific to today's subject will be addressed first, and we will get to as many questions as we possibly can. With that said, let's turn to our questions here. Dr. Palushaj, let's start with a question we heard in registration and in the chat. So this kind of jumps off of what you just said as far as suggestions.
Sandy asked what she can do going forward to improve her gut health and possibly slow or prevent progression. And similarly, Philip asked whether a diet like going meatless could change the disease progression. What can we realistically say today?
Dr. Bianca Palushaj 00:44:54
Yeah, so again, I think in terms of the first question, what I can do to support the microbiome. So again, fiber and fermented foods are really right now where we're at is kind of empirical advice for the gut microbiome. So it's a microbiome targeted diet without really being able to give specific individual advice. And so, fiber is the fuel for the microbes in order to produce those beneficial molecules. But if your microbiome doesn't have those microbes that can produce the beneficial molecules, then adding fermented foods is a great way to kind of insert those microbes as well as the byproducts into your gut.
In terms of meat, you know, I really kind of try to stay away from different camps of kind of different dogmas, so I can't speak to meat specifically.
Kirby Doshier 00:45:54
No, that is fair. Well, kind of building off of that, we have a question here that asks which dietary habits support the gut-brain connection, but more specifically, how should someone approach fiber if they're limited by gastroparesis, celiac disease, or past gastric bypass, and can a fiber supplement replace some of that food fiber?
Dr. Bianca Palushaj 00:46:18
So that's really where I think if there's kind of more unique anatomy or physiological processes going on, I think it's helpful to talk to a physician, either a GI physician or a nutritionist, because of course everyone is going to have individual responses. Again, I think going slow, increasing slowly. Some people recommend, so the low-FODMAP diet is often recommended for people with small intestinal bacterial overgrowth. I actually am not a fan of the low FODMAP diet because it involves removing a lot of those fermentable fibers.
But there are some supplements that can be added, either digestive enzymes or some other things that can be added to help people break down those hard-to-digest components of fiber. So again, go slow. Work with a nutritionist or someone who kind of knows your specific situation, and then think about adding things that can help you break down the different components. And the second portion of that question, remind me the second portion.
Kirby Doshier 00:47:30
Sorry. Let me go back. Can fiber supplements replace some of the?
Dr. Bianca Palushaj 00:47:34
Yeah. So the fiber supplement that has the best evidence for it is going to be psyllium. And so I think it's a nice supplement. You know, if you're not able to get ultimately to the goal of 30 to 40 grams through diet, maybe adding the last 20% or so with a supplement, but you don't want it to be your sole source. And again, we really want to think about a diversity of fiber sources.
Kirby Doshier 00:48:01
Great. To kind of bring this full circle between fiber and the fermented foods. One of our participants, Josh, has asked about the tyramine warnings that come with the MAO-B inhibitors and the recommendation to eat fermented foods like kimchi. How should people think about that?
Dr. Bianca Palushaj 00:48:19
Yeah, it hasn't been studied specifically. It's a great question that I don't know that I have a specific answer to. I believe that you would have to eat a lot of fermented foods in order to get to that point, but I don't know that I know.
Kirby Doshier 00:48:34
No, that is fine. I think it might be one of those things where it's also specific to region where you live. If you are in, say, an Asian country, for example, where the fermented foods are a little bit higher. That makes sense.
Dr. Bianca Palushaj 00:48:47
Yeah.
Kirby Doshier 00:48:48
Okay. And then Michael just asked for a quick recap on the foods that are key to include daily.
Dr. Bianca Palushaj 00:48:55
Yeah. So fermented foods and fiber-rich foods. I've actually oftentimes recommended, people have asked like what are some examples or how do I get 20-40 grams? I do rely on ChatGPT or some other AI models to help you come up with kind of a diet or a menu. You know, this is what I enjoy eating. Help me get to 30 to 40 grams per day. But again, I think about 10 grams of fiber per meal. So oatmeal, chia seeds, fruit in the morning. But a variety of fiber, 30 to 40 grams, and then fermented foods. I think those are the main things to add.
Kirby Doshier 00:49:44
Great, yes. Several of our participants today have asked how and when to eat around Parkinson's medication specifically. So it looks like one family is having trouble timing carbidopa-levodopa with meals because of protein, and asks whether protein is that important and whether to serve meals without it. What are some general principles you can guide us on?
Dr. Bianca Palushaj 00:50:06
Yeah, it's tricky because this can become really stressful for people, understandably. So we're asking people to take medications pretty frequently, and then it's really stressful to alter your whole daily routine around this. So the idea is that protein competes with levodopa for the transporters for absorption, and so eating a meal heavy in protein will saturate those transporters, and then the levodopa doesn't get absorbed. So generally, I think there's some variability in what practitioners will say, but I generally say take levodopa either 30 minutes before a meal or an hour after a meal. This is based on our best estimate of what the average person's gastric emptying looks like.
There's obviously variability, so this is just a broad range of what we recommend, and it is most commonly protein. But that said, thinking about the bigger picture is that, in order for levodopa to get absorbed, it has to be emptied from the stomach into the small intestine. And so anything that slows the stomach emptying into the small intestine can affect the absorption of levodopa. So that could be large, heavy meals, even if it's not heavy in protein, but just a large, rich meal can slow gastric emptying, which could then impact levodopa absorption.
I know some people, especially if patients are feeling really overwhelmed by this, some providers will say, just try it however you can get it in, and only if you're recognizing that you're not getting a good response or it's taking a long time for it to kick in, then we should think more carefully about how you're taking it in relation to food.
Kirby Doshier 00:51:58
I think that's great general practice and guidelines. Something else that's been coming up pretty frequently is constipation and bloating. They seem to be the most common concerns for this population. So what should people living with Parkinson's do when there's no urge? And they also want to know whether medications can help. What are the general approaches, and when should someone raise these concerns with their doctor?
Dr. Bianca Palushaj 00:52:24
Yeah. So part of what I advocate for, even within the neurological community, is that we as neurologists should be asking people a lot more about their constipation and their GI symptoms. I think potentially for a while patients didn't necessarily know that. You don't necessarily walk into your neurologist thinking that you're going to talk about your GI symptoms. But I would say I encourage everyone to mention it to your neurologist, and I think different neurologists will have different levels of comfort in prescribing medications. But they can always refer you to a GI doctor. So again, there's several different prescription medications. Some are older, cheaper. Some are newer and can be limited by cost.
There is one promotility agent that can be used for both delayed gastric emptying as well as delayed transit. So that's Motegrity. Oftentimes, you need to have tried other secretagogues or other classes of constipation medications before you try Motegrity, but that's one thing to think about. But I would say I just encourage everyone to talk to their neurologist about it, and again, either they will prescribe something or they can send you to a gastroenterologist who can do that. And then, without having the urge, so again, schedule toileting time. So make a routine. People like to use coffee to help them.
So thinking about having a routine in the morning, maybe after you drink coffee, or people like warm lemon water, but the same time of morning, same time of day, usually in the morning, and when you're in a good on state, and then trying to use the bathroom. Squatty Potties, so adopting that squatting position. So there's something called an actual Squatty Potty, which is a brand name. But anything that elevates your feet and raises your knees up can be helpful. I think I covered it.
Kirby Doshier 00:54:28
Yeah, no, that was fantastic. Kind of building off of that, and I think this is a timely question, where we're at in the area of Parkinson's with general neurology versus movement disorder specialists. But we have a participant today, Kathy, who has a gastroenterologist, but they don't seem to know a lot about the relationship between the gut and PD. So how can they, or anyone living with PD, maybe help connect their providers with this information to help them treat?
Dr. Bianca Palushaj 00:55:02
Yeah, it's a very good question. And part of what I'm really interested in doing is spreading education and awareness to both neurologists and gastroenterologists. For better or worse, the medications that we use for constipation in Parkinson's are not unique to Parkinson's. So unfortunately, we don't have any that are specifically approved for Parkinson's constipation. So a GI doctor should still be comfortable prescribing, or knowledgeable about prescribing, any of these medications for chronic idiopathic constipation or IBS constipation. Most of these medications have been approved for those two indications that I mentioned, and we happen to use them for Parkinson's constipation.
Kirby Doshier 00:55:47
Similarly, do you recommend a registered dietitian versus a nutritionist, even though some of these people with Parkinson's may be seeing gastroenterologists already?
Dr. Bianca Palushaj 00:55:58
I think it's so person-dependent. I think it can become complicated if someone is found to have small intestinal bacterial overgrowth and gastroparesis and slow transit constipation, and then changes in appetite, which is common with Parkinson's disease, but certainly with loss of smell and trouble swallowing. And so, in those instances, we're really aiming for a fiber-rich diet, but it can provoke a lot of symptoms, and it's a complicated situation. I don't want people minimizing protein, but I think protein often gets minimized because of this complication with levodopa. And so I recognize it's a lot to think about.
And so a nutritionist or a dietitian can be helpful if someone has access to that.
Kirby Doshier 00:56:52
Sounds like they may be more helpful on the day-to-day organization of how you're eating and what you're eating versus those regular checkups in relation to the medication that you're taking, things like that.
Dr. Bianca Palushaj 00:57:02
Yeah, yeah.
Kirby Doshier 00:57:03
This is kind of a fun one, and I think it's relatable to a lot of us that are coffee drinkers. But Dawn asked that they've heard of some indications that coffee may be beneficial for those with PD. Do you know of any indication of how coffee relates to gut health and PD?
Dr. Bianca Palushaj 00:57:18
I don't. I don't know that I've seen the literature with coffee and PD. I've seen some that coffee may be protective against neurodegenerative disease broadly. I can't say that I've read the literature in great detail. Sorry.
Kirby Doshier 00:57:33
No, that's okay. We have one clarification question from Tamara. They thought that you said laxatives don't work, but then during the conversation around slow transit constipation, you mentioned that the treatment included taking laxatives such as MiraLAX. Can you please help?
Dr. Bianca Palushaj 00:57:53
Yeah. So what I was saying is that laxatives don't help dyssynergic defecation, right? So there's slow transit constipation and there's dyssynergic defecation, which is that outlet obstruction that leads to straining and a sense of incomplete evacuation, and that is a pelvic floor coordination problem. And so you could take all the laxatives and improve your stool content and your motility, but still have dyssynergic defecation. And so the treatment for slow transit constipation is going to be the laxatives, and the treatment for dyssynergia is biofeedback.
Kirby Doshier 00:58:38
Thank you. That's a very helpful recap. Let's turn to one of the most talked-about microbiome treatments from today. Virginia asked about fisetin specifically, and then another attendee asked about photobiomodulation and the microbiome. So really, I think the questions are around how people should think about approaching this very early emerging research and implementing it into their daily routines now.
Dr. Bianca Palushaj 00:59:06
Sorry, what was the first portion? I don't know that I'm understanding the question.
Kirby Doshier 00:59:08
Oh, I'm sorry. It's just a little more of the specifics around fisetin, and then also about photobiomodulation and the microbiome. So because this is early emerging research, how should people be thinking about and approaching that, utilizing what information is out there in their daily lives now?
Dr. Bianca Palushaj 00:59:28
I'm not familiar with fisetin.
Kirby Doshier 00:59:31
I might be saying it wrong. It's F-I-S-E-T-I-N. It's a plant flavonoid.
Dr. Bianca Palushaj 00:59:40
Okay. I don't know this literature. Yeah, I don't know the literature, and I really don't know the literature for photomodulation either.
Kirby Doshier 00:59:47
Okay.
Dr. Bianca Palushaj 00:59:48
We know that there's a circadian—you know, the microbiome has a circadian rhythm as well, and certainly timing of meals and light exposure can impact the microbiome. But I can't say much more about it than that.
Kirby Doshier 01:00:07
No, that is still very, very useful information. We heard a lot from our care partners in the chat as well. So a care partner asks how to help make a spouse with Parkinson's more comfortable. What can care partners do about gut and eating challenges?
Dr. Bianca Palushaj 01:00:28
This is a broad question. What can caregivers do to help with gut and eating challenges? I mean, outside of the things that we've discussed, I think understanding what this person's food preferences are. Yeah, I don't...
Kirby Doshier 01:00:56
I think it can vary. I think it really varies on the situation, the amount of involvement of the care partners, probably specific diet needs as well. So very understandable that that answer can vary person to person. We have time for a couple more here. Looks like one that keeps getting asked is around GLP-1s. So do you know of any GLP-1 interference with Parkinson's disease treatment as it relates to the gut-brain interaction?
Dr. Bianca Palushaj 01:01:27
This is obviously a newer area, and this has come up clinically. But to my knowledge, there's not really any guidelines out there about GLP-1s and the potential interaction with levodopa. So part of what the GLP-1s do is slow gastric emptying, which, as we know, is often slow in people with Parkinson's, and then levodopa also can further slow gastric emptying. And as mentioned, slow gastric emptying can make levodopa sit in the stomach longer, where it gets degraded, and then less of it gets into the small intestine for absorption. And so, just anecdotally within our division, there are definitely patients who weren't on GLP-1s and then now are on GLP-1s and have had a more erratic response to levodopa that we are attributing to the delayed gastric emptying from the GLP-1s.
Specifically, you would think about delayed on time and just less of a robust on time. But I think it's a case-by-case basis. This actually came up recently for me with a patient, and I ended up sending them to GI to discuss. I don't know if it would be reasonable to start a promotility agent at the same time. This patient really didn't want to come off the GLP-1, but I think the short answer is it can interfere.
And anecdotally, we are seeing that, but there are no guidelines specifically about how to manage it.
Kirby Doshier 01:03:05
That's fantastic insight. I do think that this is a very hot topic in many different communities, and so definitely looking forward to what that research will look like moving forward. We have a great question: How can I become a part of the Gut-Brain Consortium study?
Dr. Bianca Palushaj 01:03:19
Wonderful. So there is a website. It's gutbrainparkinsons.com. But I would say, depending on where this person lives, whichever site you're closest to, I would Google that movement disorders division at that site and then find the contact information. Also, we have an email address at Stanford that's gutbrainresearch@stanford.edu, and so anyone is welcome to email that address, and then we can get you in contact with the site that's closest to you. So I'd say two avenues, but definitely check out the website as well.
Kirby Doshier 01:04:15
Awesome, that's exciting. I always encourage, if you can be a part of a study, please, please, please do it. All right. Looks like we have about 10 more minutes here, so we'll just keep chugging along. Okay. Bill asks, 'How does PD affect colonoscopy prep? They have tried four times this year and did not successfully get clear discharge.'
Dr. Bianca Palushaj 01:04:37
Oh, bummer. I'm so sorry to hear that. As a non-gastroenterologist, I don't know. I would talk to your GI doctor about that. I mean, probably what I've heard anecdotally is just prolonged, not necessarily prep, but a prolonged time on the clear liquid diet before. So in general, because people with Parkinson's can have such prolonged transit time, whereas, let's say, two days is enough on a clear liquid diet for the average person, someone with slower transit could need three or four days on that clear liquid diet. But I would talk to your GI doctor.
Kirby Doshier 01:05:19
I think similarly, a lot of people are asking about comorbid diseases or illnesses with PD, such as colon cancer. Can you comment on any of that and, I guess, ways to track inflammation, if it's possible, especially with those with comorbid diseases?
Dr. Bianca Palushaj 01:05:41
Yeah, I don't know if I understand the question on comorbid disease, the relationship. I mean, I think, as probably a lot of us know, chronic diseases and diseases of inflammation are on the rise, right? So autoimmune disease, cancers. Parkinson's disease is the fastest-growing neurological disorder. So I think the verdict is still out on why this is the case. Probably chronic inflammation is driving a lot of these things. In terms of markers that we have, clinically we don't really routinely use markers of GI inflammation in Parkinson's care. So doctors that treat inflammatory bowel disease, or IBD, will use things like fecal calprotectin.
From a research perspective, you can check markers of barrier permeability and things like that, but we don't use them routinely in clinical care.
Kirby Doshier 01:06:42
Elaine asked if intermittent fasting can help, and if so, is there an optimum number of hours for fasting?
Dr. Bianca Palushaj 01:06:54
Yeah, good question. Again, I don't have a great evidence base. I mean, it's complicated and it's complex, and I think that especially for women, from what I understand, with reproductive hormones and such, that can have a different impact, and intermittent fasting can have a different impact. I'd say in general, I think I agree with the recommendation that we generally should give our gut, both our gut as well as the gut microbiome, about 12 hours of rest overnight. So I think people will say bare minimum 10 hours, but aim for 12 hours. And I know people go up to 16 hours, but I think it really depends on the person.
Kirby Doshier 01:07:38
Great. Leah asks, 'What seems to have more influence: short-chain fatty acids and/or different neuroprotective antioxidants?'
Dr. Bianca Palushaj 01:07:49
I mean, I wouldn't think of them as a direct comparison, that one has more influence than the other. I'm not sure which neuroprotective antioxidants they're referring to, but short-chain fatty acids act systemically, of course, on the brain, but also throughout the body. So I would think of them as synergistic, as opposed to comparing them to each other.
Kirby Doshier 01:08:21
That's great. All right, just a couple more here. One: How do common medications, such as lots of aspirin, affect the gut microbiome?
Dr. Bianca Palushaj 01:08:33
I don't know. I don't know specifically the study of aspirin on—I mean, most medications have an impact on the microbiome. Some of these have been studied, and some of them haven't. But I don't know the literature specifically for aspirin and the microbiome.
Kirby Doshier 01:08:49
That's fine. No, I think we've discussed a lot of amazing topics here. I think you've had a lot of great insight for everyone. One question I want to end this with is: If there's one thing you would like people to remember from today, what would that be?
Dr. Bianca Palushaj 01:09:03
Great question. I think, from a practical standpoint, I hope that people feel empowered, that we can do a lot to support our microbiome, and that microbiome health is gut health, is brain health, is whole-body health. And I think the other point is, in the future, I think that there's a lot of really promising, exciting gut-targeted therapies for Parkinson's disease. And again, this could be symptomatic therapies to treat symptoms of GI dysfunction, but also potentially to modify disease.
Kirby Doshier 01:09:40
That's fantastic. Thank you so much, Dr. Palushaj, for offering your time today for this expert briefing. I really hope everyone was able to take away something new and something helpful. And a big thank you to each of you who have joined us today.
Dr. Bianca Palushaj 01:09:56
Thank you, Kirby. Thank you so much, everyone, for being here.
Kirby Doshier 01:10:01
Thank you. I'm just going to share my screen here real quick. Oh, here we go. All right, share. Move this off. Awesome. All right, thank you again. We understand that we had a significant response during our Q&A session. If we were not able to get to your question today, please call our Helpline at 1-800-473-4636, or you can also email our Helpline at Helpline@Parkinson.org. Our next expert briefing will take place on November 11, and this session will examine what is known and what remains uncertain about environmental exposures, genetic vulnerability and protective factors. You can learn more and register at Parkinson.org/ExpertBriefings. In addition to our expert briefings, the Parkinson's Foundation offers a range of virtual education and wellness programs through our PD Health at Home series.
You can learn more about these programs at the webpage on your screen, Parkinson.org/PDHealth. You can also register there as well. Please do not hesitate to reach out to the Parkinson's Foundation. We have a very comprehensive website and also our PAM Chat tool on our website. We have many more resources that address everything related to PD at Parkinson.org. Please also feel free to call our Helpline at 1-800-473-4636 or email us at Helpline@Parkinson.org. We are more than happy to have a conversation, point you to any answers or resources that you may need.
We really hope you all take care today, and we look forward to seeing you on our next expert briefing. Thank you.